Kymera Therapeutics KYMR Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's operating lease right-of-use assets in other assets?
- Kymera Therapeutics (KYMR) reported operating lease right-of-use assets in other assets of $41.74M in Q1 2026.
- How has Kymera Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
- Kymera Therapeutics's operating lease right-of-use assets in other assets decreased by 10.7% year-over-year, from $46.73M to $41.74M.
- What is the long-term trend for Kymera Therapeutics's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Kymera Therapeutics's operating lease right-of-use assets in other assets has grown at a 33.9% compound annual growth rate (CAGR), from $9.85M to $42.35M.